التفاصيل البيبلوغرافية
| العنوان: |
Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow‐up results of phase IIa clinical study. |
| المؤلفون: |
Yoshida, Osamu, Akbar, Sheikh Mohammad Fazle, Imai, Yusuke, Sanada, Takahiro, Tsukiyama‐Kohara, Kyoko, Miyazaki, Takashi, Kamishita, Taizou, Miyake, Teruki, Tokumoto, Yoshio, Hikita, Hayato, Tsuge, Masataka, Shimizu, Masahito, Al Mahtab, Mamun, Aguilar, Julio Cesar, Guillen, Gerardo, Kohara, Michinori, Hiasa, Yoichi |
| المصدر: |
Hepatology Research; Mar2023, Vol. 53 Issue 3, p196-207, 12p |
| مصطلحات موضوعية: |
CHRONIC hepatitis B, VINYL polymers, SUBCUTANEOUS injections, VACCINE effectiveness |
| مستخلص: |
Aims: HBsAg loss with anti‐HBs acquisition is considered a functional cure and ideal treatment goal for patients with CHB. Our group have reported the efficacy of therapeutic vaccine with HBsAg and HBcAg (NASVAC) by intranasal and subcutaneous injection. In this study, we investigated the safety and efficacy of newly developed CVP‐NASVAC, which contained NASVAC with mucoadhesive carboxyl vinyl polymer (CVP) in the dedicated device. Methods: A single dose, open‐label, phase IIa clinical trial of CVP‐NASVAC was conducted. Patients with CHB treated with nucleoside/nucleotide analogs (NAs) and HBV carriers not undergoing anti‐HBV treatment were enrolled. CVP‐NASVAC was injected through the nose for, in total, 10 times. Participants were followed‐up for 18 months, and their HBsAg reduction and anti‐HBs induction assessed as endpoints. Results: Among the patients with CHB treated with NAs (n = 27) and HBV carriers without NAs (n = 36), 74.1% and 75.0% exhibited reductions in their baseline HBsAg, and the mean reductions were −0.1454 log10 IU/ml (p < 0.05) and −0.2677 log10 IU/ml (p < 0.05), respectively. Anti‐HBs antibody was detected in 40.7% and 58.3% of patients treated with and without NAs, respectively. Six of 71 (9.5%) patients were functionally cured after the CVP‐NASVAC treatment. Conclusions: Anti‐HBs induction and HBsAg reduction was observed after CVP‐NASVAC treatment in some patients with CHB. The CVP‐NASVAC is a safe treatment, which might expect to achieve functional cure for patients with CHB. [ABSTRACT FROM AUTHOR] |
|
Copyright of Hepatology Research is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
